Joshua Hefler1, Braulio A Marfil-Garza1,2,3, Sandra Campbell4, Darren H Freed5, A M James Shapiro1,6. 1. Division of General Surgery, Department of Surgery, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, Canada. 2. National Institutes of Medical Sciences & Nutrition Salvador Zubiran, Mexico City, Mexico. 3. CHRISTUS-LatAm Hub Excellence & Innovation Center, Monterrey, Mexico. 4. John W. Scott Health Sciences Library, University of Alberta, Edmonton, Canada. 5. Division of Cardiac Surgery, Department of Surgery, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, Canada. 6. Clinical Islet Transplant Program, University of Alberta, Edmonton, Canada.
Abstract
Background: Though best known for its immunosuppressant effects, cyclosporine A (CsA) has also been studied as a treatment to mitigate ischemia-reperfusion injury (IRI) by its inhibition of the mitochondria permeability transition pore (mPTP). Despite numerous preclinical studies supporting its benefit in reducing infarct size following myocardial IRI, large randomized controlled clinical trials have been unable to show a beneficial effect. Exploring existing preclinical data can give us the opportunity to revisit some the assumptions that may have led to the failure of these studies to translate clinically. Herein, we present a systematic review of preclinical studies testing CsA to attenuate myocardial IRI (PROSPERO CRD42020159620). Methods: We conducted a systematic search of health research databases Ovid MEDLINE, Ovid EMBASE, Web of Science BIOSIS, and Scopus, as well as Cochrane and PROSPERO systematic review databases, on March 9, 2022 for non-human in vivo animal studies of myocardial IRI, using CsA as a treatment that reported clinically relevant outcomes. Bias was assessed using the Systematic Review Centre for Laboratory Animal Experimentation's risk of bias tool and a modified Collaborative Approach to Meta Analysis and Review of Animal Data from Experimental Studies checklist. Sub-group meta-analyses were conducted to identify potential factors influencing outcomes. Results: We identified 71 studies, 59 of which were studies of coronary occlusion. Overall, 75% of studies reported a clear positive effect of CsA in mitigating myocardial IRI by some clinically relevant parameter (e.g., infarct size). A meta-analysis including 43 coronary occlusion studies showed an overall reduction in infarct size with CsA treatment (16.09%; 95% CI: -18.50% to -13.67%). Subgroup meta-analyses identified species, age, timing of administration, and duration of ischemia as factors potentially affecting the efficacy of CsA in the setting of myocardial IRI. Conclusions: Our systematic review and meta-analysis identifies questions that have yet to be answered by preclinical studies, highlighting important differences between these and clinical studies that should be addressed prior to proceeding with any further clinical studies using CsA to treat IRI in the heart or other organs. We also use the example of CsA to highlight general considerations for researchers attempting to translate animal studies into the clinical setting. 2022 Annals of Translational Medicine. All rights reserved.
Background: Though best known for its immunosuppressant effects, cyclosporine A (CsA) has also been studied as a treatment to mitigate ischemia-reperfusion injury (IRI) by its inhibition of the mitochondria permeability transition pore (mPTP). Despite numerous preclinical studies supporting its benefit in reducing infarct size following myocardial IRI, large randomized controlled clinical trials have been unable to show a beneficial effect. Exploring existing preclinical data can give us the opportunity to revisit some the assumptions that may have led to the failure of these studies to translate clinically. Herein, we present a systematic review of preclinical studies testing CsA to attenuate myocardial IRI (PROSPERO CRD42020159620). Methods: We conducted a systematic search of health research databases Ovid MEDLINE, Ovid EMBASE, Web of Science BIOSIS, and Scopus, as well as Cochrane and PROSPERO systematic review databases, on March 9, 2022 for non-human in vivo animal studies of myocardial IRI, using CsA as a treatment that reported clinically relevant outcomes. Bias was assessed using the Systematic Review Centre for Laboratory Animal Experimentation's risk of bias tool and a modified Collaborative Approach to Meta Analysis and Review of Animal Data from Experimental Studies checklist. Sub-group meta-analyses were conducted to identify potential factors influencing outcomes. Results: We identified 71 studies, 59 of which were studies of coronary occlusion. Overall, 75% of studies reported a clear positive effect of CsA in mitigating myocardial IRI by some clinically relevant parameter (e.g., infarct size). A meta-analysis including 43 coronary occlusion studies showed an overall reduction in infarct size with CsA treatment (16.09%; 95% CI: -18.50% to -13.67%). Subgroup meta-analyses identified species, age, timing of administration, and duration of ischemia as factors potentially affecting the efficacy of CsA in the setting of myocardial IRI. Conclusions: Our systematic review and meta-analysis identifies questions that have yet to be answered by preclinical studies, highlighting important differences between these and clinical studies that should be addressed prior to proceeding with any further clinical studies using CsA to treat IRI in the heart or other organs. We also use the example of CsA to highlight general considerations for researchers attempting to translate animal studies into the clinical setting. 2022 Annals of Translational Medicine. All rights reserved.
Authors: J J Bogaards; M Bertrand; P Jackson; M J Oudshoorn; R J Weaver; P J van Bladeren; B Walther Journal: Xenobiotica Date: 2000-12 Impact factor: 1.908
Authors: R Y Calne; K Rolles; D J White; S Thiru; D B Evans; P McMaster; D C Dunn; G N Craddock; R G Henderson; S Aziz; P Lewis Journal: Lancet Date: 1979-11-17 Impact factor: 79.321
Authors: Jiang Zhu; Mario J Rebecchi; Qiang Wang; Peter S A Glass; Peter R Brink; Lixin Liu Journal: Am J Physiol Heart Circ Physiol Date: 2012-12-28 Impact factor: 4.733
Authors: T Kurokawa; H Kobayashi; T Nonami; A Harada; A Nakao; S Sugiyama; T Ozawa; H Takagi Journal: Transplantation Date: 1992-02 Impact factor: 4.939
Authors: Filippo Ottani; Roberto Latini; Lidia Staszewsky; Luigi La Vecchia; Nicola Locuratolo; Marco Sicuro; Serge Masson; Simona Barlera; Valentina Milani; Mario Lombardi; Alessandra Costalunga; Nadia Mollichelli; Andrea Santarelli; Nicoletta De Cesare; Paolo Sganzerla; Alberto Boi; Aldo Pietro Maggioni; Ugo Limbruno Journal: J Am Coll Cardiol Date: 2016-02-02 Impact factor: 24.094